These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 35740212)

  • 1. Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems.
    van Staden D; Haynes RK; Viljoen JM
    Antibiotics (Basel); 2022 Jun; 11(6):. PubMed ID: 35740212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
    Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofazimine for the treatment of tuberculosis.
    Stadler JAM; Maartens G; Meintjes G; Wasserman S
    Front Pharmacol; 2023; 14():1100488. PubMed ID: 36817137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofazimine: A useful antibiotic for drug-resistant tuberculosis.
    Mirnejad R; Asadi A; Khoshnood S; Mirzaei H; Heidary M; Fattorini L; Ghodousi A; Darban-Sarokhalil D
    Biomed Pharmacother; 2018 Sep; 105():1353-1359. PubMed ID: 30021373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
    Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.
    Zhang Z; Li T; Qu G; Pang Y; Zhao Y
    Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Self-Emulsifying Drug Delivery System for Optimized Topical Delivery of Clofazimine.
    van Staden D; du Plessis J; Viljoen J
    Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32521671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.
    Dey T; Brigden G; Cox H; Shubber Z; Cooke G; Ford N
    J Antimicrob Chemother; 2013 Feb; 68(2):284-93. PubMed ID: 23054996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofazimine in the treatment of multidrug-resistant tuberculosis.
    Xu HB; Jiang RH; Xiao HP
    Clin Microbiol Infect; 2012 Nov; 18(11):1104-10. PubMed ID: 22192631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Tuberculosis Antimicrobials on the Immunometabolic Profiles of Primary Human Macrophages Stimulated with
    Cahill C; Cox DJ; O'Connell F; Basdeo SA; Gogan KM; Ó'Maoldomhnaigh C; O'Sullivan J; Keane J; Phelan JJ
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant
    Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K
    Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
    He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
    J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.